Competition binding constant values (Ki) were determined
by HTRF binding assay. The values of potency (EC50) and
efficacy (Emax, normalized to DAMGO) come from cAMP
assays performed on CHO-MOR (WT & W6.48L) cells and β-arrestin2
recruitment performed on CHO-MOR (WT & W6.48L)-β-arrestin2 cells. Data
were presented as mean ± SEM of three or more assays run in duplicate or
triplicate. The difference between Ki,
EC50, and Emax values of wild-type
versus W6.48L mutant MOR was acquired via unpaired, two-tailed t-test.
The corresponding binding curves were shown in Figure 2 , and
corresponding dose-response curves were shown in Figure 3 .
Table
2 Bias analysis of test agonists for wild-type and W6.48L mutant MOR